[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"macular-degeneration-choroidal-neovascularization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:macular-degeneration-choroidal-neovascularization":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100573132","phase-4-faricimab-quarterly-maintenance-for-neovascular-age-related-macular-degeneration-100573132",false,"NCT06742307","Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration","Faricimab Fixed Quarterly Maintenance for Neovascular Age Related Macular Degeneration: A Prospective Case Series","Fixed farcimab","Inclusion Criteria:\n\nSubjects aged over 50 years, neovascular AMD with foveal involvement, both treatment-naïve and recurrent cases. There were no specific criteria for initial best-corrected visual acuity (BCVA). Only active subfoveal MNV are included, including types 1, 2, and 3.\n\nExclusion Criteria:\n\n* eyes that received any anti-VEGF therapy in the prior six months,\n* eyes with other disease entities (e.g., diabetic macula oedema, retinal vein occlusions, central serous chorioretinopathy, myopicmacular neovascularisation),\n* concurrent macula laser (except photodynamic therapy) and ocular surgery (e.g., cataract surgery or vitrectomy) in the prior six months and the study period.","ALL","50 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.",[27],"Macular Degeneration Choroidal Neovascularization",[29,30],"neovascular age related macular degeneration","faricimab","RECRUITING","2025-09-26",{"date":34,"type":35},"2025-10-01","ACTUAL",{"date":37,"type":35},"2025-08-21",{"date":39,"type":21},"2027-02-01",{"name":41,"class":42},"Hospital Authority, Hong Kong","OTHER_GOV","Macular Degeneration, Choroidal Neovascularization"]